Log in or Register for enhanced features | Forgotten Password?
White Papers | Suppliers | Events | Report Store | Companies | Dining Club | Medical Devices | Videos
Contract Research & Services
Contract Services
Return to: PBR Home | Contract Research & Services | Contract Services

Contract Services

Regeneron, Sanofi launch new immuno-oncology collaboration Regeneron Pharmaceuticals and Sanofi have entered into a new global collaboration to discover, develop and commercialize new antibody cancer treatments in the emerging field of immuno-oncology.
Contract Research & Services > Contract Services > News
Boehringer, Hanmi to develop third generation EGFR targeted therapy in lung cancer By PBR Staff Writer
Boehringer Ingelheim has entered into an exclusive license and collaboration agreement with Hanmi Pharmaceutical for the development and global commercialisation rights of HM61713, a new third generation EGFR targeted therapy to treat EGFR mutation positive lung cancer.
Contract Research & Services > Contract Services > News Sanofi's Genzyme agrees to buy AstraZeneca's rare disease therapy Caprelsa for $300m By PBR Staff Writer
Sanofi's Genzyme has entered into a definitive agreement with AstraZeneca to acquire Caprelsa (vandetanib), a rare disease therapy, for about $300m.
Contract Research & Services > Contract Services > News
See more Contract Services news

Latest Contract Services News and Insight

View all Contract Services news or find news targeted to your interests
Bloomage, Medytox set up new JV to jointly develop Botulinum Toxin market in China
Bloomage BioTechnology announces a strategic cooperation with the South Korean BioTech Company Medytox to establish a joint venture Medybloom to develop and promote Type A Botulinum Toxin (Botulinum Toxin) business in China.
Contract Research & Services > Contract Services > News
Knight Therapeutics to manage regulatory, commercial activities for AzaSite in Canada
By PBR Staff Writer
Canadian pharmaceutical firm Knight Therapeutics has signed an exclusive agreement with Akorn for the exclusive distribution of AzaSite (azithromycin ophthalmic solution) in Canadian markets.
Contract Research & Services > Contract Services > News
TTY Biopharm to market PharmaMar's Aplidin in Taiwan to treat hematological cancers
By PBR Staff Writer
Spain-based PharmaMar has entered into an exclusive license and commercialization agreement with TTY Biopharm to market and distribute the drug candidate Aplidin (plitidepsin) in Taiwan for the treatment of hematological cancers.
Contract Research & Services > Contract Services > News
Ablynx expands immuno-oncology collaboration with Merck
By PBR Staff Writer
Belgian biopharmaceutical firm Ablynx has expanded its immuno-oncology collaboration with a subsidiary of Merck to address an increased number of immune checkpoint modulator targets.
Contract Research & Services > Contract Services > News
Pfizer expands lease agreement with Kendall Square for research facility
By PBR Staff Writer
Pfizer has expanded its lease agreement with a subsidiary of Massachusetts Institute of Technology, creating a unified Pfizer campus in Kendall Square (KSQ) to help expedite discovery and development efforts.
Contract Research & Services > Contract Services > News
Spero achieves first milestone payment in anti-infective partnership with Roche
Spero Therapeutics, a biopharmaceutical company founded to develop novel therapies for the treatment of bacterial infections, announced that the company received its first milestone payment from Roche as part of the companies’ ongoing collaboration on Spero’s Multiple virulence factor Regulator (MvfR) inhibitor program of anti-infectives.
Contract Research & Services > Contract Services > News
Knight Therapeutics gets exclusive distribution rights of Alimera's Iluvien in Canada to treat DME
By PBR Staff Writer
US-based Alimera Sciences has signed an exclusive agreement with Canadian pharmaceutical firm Knight Therapeutics for the distribution of Iluvien in Canada.
Contract Research & Services > Contract Services > News
AstraZeneca divests non-US rights of Entocort to Tillotts Pharma for $215m
By PBR Staff Writer
AstraZeneca has completed the divestment of non-US global rights of its gastroenterology drug Entocort to Tillotts Pharma (Tillotts), part of the Zeria Group, for $215m.
Contract Research & Services > Contract Services > News
AstraZeneca, Kyowa Hakko to commercialize benralizumab in Japan for asthma and COPD
By PBR Staff Writer
AstraZeneca and Kyowa Hakko Kirin have entered into an agreement for an exclusive option to commercialize benralizumab, a monoclonal antibody, for the treatment of asthma and chronic obstructive pulmonary disease (COPD) in Japan.
Contract Research & Services > Contract Services > News
CANbridge to develop and commercialize Apogenix’s APG101 in glioblastoma for China
By PBR Staff Writer
US-based CANbridge Life Sciences has entered into an exclusive license agreement with Apogenix, to develop, manufacture and commercialize the latter's lead product, APG101.
Contract Research & Services > Contract Services > News
View all Contract Services news or find news targeted to your interests